소아용 의약품 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the pediatric drugs market size was valued at USD 141.27 billion in 2025 and estimated to grow from USD 152.97 billion in 2026 to reach USD 227.67 billion by 2031, at a CAGR of 8.29% during the forecast period (2026-2031).

This report Segments the Industry Into Drug Type (Respiratory Disorder Drugs, Autoimmune Disorder Drugs, Gastrointestinal Drugs, Cardiovascular Drugs, Other Drug Types), Route of Administration (Oral, Topical, Parenteral, Other Routes of Administration) and Geography. The Market Sizes and Forecasts are Provided in Terms of Value (USD).

Global Pediatric Drugs Market Trends and Insights

Growing Burden of Chronic Pediatric Illnesses

Childhood obesity affects 6 million U.S. children, and therapies such as liraglutide now target ages 6-12 . Rising prevalence of complex neurological disorders has led to approvals like KEBILIDI for aromatic L-amino acid decarboxylase deficiency . Pediatric oncology similarly shifts toward nanomedicine, where exosome-based carriers enhance drug targeting and reduce systemic toxicity. Longer treatment horizons magnify the need for safe, palatable formulations and reinforce demand in the pediatric drugs market.

Expanding R&D Pipelines & Pediatric-Exclusive Designations

The FDA issued 38 rare pediatric disease priority review vouchers through 2024, sparking 569 designations since 2013, most in neurology, metabolism, and oncology. Companies rushed applications before the program sunset in December 2024, increasing deal-making momentum exemplified by Merck KGaA's USD 3.9 billion SpringWorks acquisition for the neurofibromatosis therapy GOMEKLI. Firms are now designing drugs specifically for pediatric physiology, illustrated by BioCryst's planned NDA for ORLADEYO granules for children under 12. These moves strengthen innovation depth within the pediatric drugs market.

Ethical & Recruitment Hurdles in Pediatric Trials

Only 10% of eligible children enroll in trials because parents weigh risks carefully and IRB processes vary across sites. Language-related consent barriers further lower participation among Black and Hispanic families . Deferred consent models in neonatal studies aim to reconcile urgency with ethics. These hurdles slow evidence generation for the pediatric drugs market.

Other drivers and restraints analyzed in the detailed report include:

1. Government Incentives for Orphan & Pediatric Drugs
2. Expansion of Pediatric Vaccination Schedules in Emerging Markets
3. Real-World Evidence Accelerating Age-Appropriate Dosing
4. Digital Adherence Platforms Boosting Treatment Outcomes
5. High Palatability / Formulation Costs

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Respiratory treatments captured 25.22% of 2025 revenue in the pediatric drugs market as corticosteroid dependence and recent shortages sustained demand. The launch of albuterol / budesonide combination inhalers alleviates supply pressure and enhances dual-action therapy. Neurology and ADHD agents grow at 8.96% CAGR through 2031 as diagnostic clarity rises and non-stimulant options gain favor. Oncology pipelines integrate exosome-based nanocarriers that widen the therapeutic window for cytotoxics. Collectively, therapeutic diversification secures resilience in the pediatric drugs market.

The segment also includes autoimmune breakthrough therapies such as LENMELDY, which highlight curative potential in ultrarare leukodystrophies. Gastrointestinal drugs are affected by stewardship programs that keep empirical antibiotic usage in check, while cardiovascular agents benefit from emerging real-world safety data. Across categories, firms increasingly design pediatric-specific formulations rather than scaling down adult products, ensuring compliance with taste, texture, and dose-flexibility requirements intrinsic to the pediatric drugs market.

Complete Report Scope:

• By Drug Type
  • Respiratory Disorder Drugs
  • Autoimmune Disorder Drugs
  • Gastrointestinal Drugs
  • Cardiovascular Drugs
  • Neurology & ADHD Drugs
  • Oncology Drugs
  • Other Drug Types
• By Route of Administration
  • Oral
  • Topical
  • Parenteral
  • Inhalation
  • Other Routes
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores
  • Online Pharmacies
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America commanded 39.85% of the pediatric drugs market in 2025 on the back of robust regulatory frameworks, insurance coverage for specialty formulations, and early technology adoption. The FDA granted multiple priority review vouchers in 2024 for products such as XOLREMDI and DUVYZAT, reinforcing the region's attractiveness. Supply shocks like the withdrawal of established inhaled steroids highlighted vulnerability to single-product reliance, yet the maturity of telemedicine and home-based monitoring supports continuity of care and future expansion.

Asia-Pacific is forecast to grow at 10.32% CAGR to 2031, making it the fastest-expanding region in the pediatric drugs market. China registered 895 pediatric clinical trials between 2013-2022 and now emphasizes innovative over generic pipelines. India's USD 250 million Gavi partnership targets a 30% reduction in zero-dose children, while successful nationwide pneumococcal vaccine implementation underscores capability to scale. Japan advances gene therapy approvals such as OTL-200, signaling regional strength in precision medicine.

Europe sustains moderate growth despite chronic shortages that affected 779 pediatric medicines from 2001-2015. The EMA facilitates centralized pediatric oversight, yet logistical complexities post-Brexit necessitate new supply configurations. Germany adopted RSV prophylaxis for infants, evidencing evidence-driven uptake of novel biologics. In the Middle East and Africa, conditional cash transfers doubled immunization rates in Nigerian pilot areas, and similar programs could uplift coverage across the continent. South America faces headwinds as DTP3 rates dropped to 75% in 2021, but combination-vaccine reforms in Colombia and Peru offer templates for recovery. These divergent trajectories create geographically diverse opportunities within the pediatric drugs market.

1. Pfizer
2. Johnson & Johnson
3. GlaxoSmithKline
4. Sanofi
5. Novartis
6. PTC Therapeutics
7. Biomarin Pharmaceutical
8. Horizon Therapeutics
9. Jazz Pharmaceuticals plc
10. Gilead Sciences
11. Sumitomo Pharma Co. Ltd.
12. Boehringer Ingelheim
13. Roche
14. Eli Lilly and Company
15. Amgen
16. CSL Seqirus
17. AstraZeneca
18. Merck
19. Abbvie
20. Takeda Pharmaceutical Co.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Growing burden of chronic pediatric illnesses
  • 4.2.2 Expanding R&D pipelines & pediatric-exclusive designations
  • 4.2.3 Government incentives for orphan & pediatric drugs
  • 4.2.4 Expansion of pediatric vaccination schedules in emerging markets
  • 4.2.5 Real-world evidence accelerating age-appropriate dosing
  • 4.2.6 Digital adherence platforms boosting treatment outcomes
• 4.3 Market Restraints
  • 4.3.1 Ethical & recruitment hurdles in pediatric trials
  • 4.3.2 High palatability/formulation costs
  • 4.3.3 Antibiotic-stewardship pressure on prescriptions
  • 4.3.4 Supply-chain gaps for taste-masking excipients
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers/Consumers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitute Products
  • 4.7.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD Million)

• 5.1 By Drug Type
  • 5.1.1 Respiratory Disorder Drugs
  • 5.1.2 Autoimmune Disorder Drugs
  • 5.1.3 Gastrointestinal Drugs
  • 5.1.4 Cardiovascular Drugs
  • 5.1.5 Neurology & ADHD Drugs
  • 5.1.6 Oncology Drugs
  • 5.1.7 Other Drug Types
• 5.2 By Route of Administration
  • 5.2.1 Oral
  • 5.2.2 Topical
  • 5.2.3 Parenteral
  • 5.2.4 Inhalation
  • 5.2.5 Other Routes
• 5.3 By Distribution Channel
  • 5.3.1 Hospital Pharmacies
  • 5.3.2 Retail Pharmacies & Drug Stores
  • 5.3.3 Online Pharmacies
• 5.4 By Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East & Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East & Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Pfizer Inc.
  • 6.3.2 Johnson & Johnson (Janssen)
  • 6.3.3 GlaxoSmithKline plc
  • 6.3.4 Sanofi SA
  • 6.3.5 Novartis AG
  • 6.3.6 PTC Therapeutics Inc.
  • 6.3.7 BioMarin Pharmaceutical Inc.
  • 6.3.8 Horizon Therapeutics plc
  • 6.3.9 Jazz Pharmaceuticals plc
  • 6.3.10 Gilead Sciences Inc.
  • 6.3.11 Sumitomo Pharma Co. Ltd.
  • 6.3.12 Boehringer Ingelheim GmbH
  • 6.3.13 F. Hoffmann-La Roche Ltd
  • 6.3.14 Eli Lilly and Company
  • 6.3.15 Amgen Inc.
  • 6.3.16 CSL Seqirus
  • 6.3.17 AstraZeneca plc
  • 6.3.18 Merck & Co., Inc.
  • 6.3.19 AbbVie Inc.
  • 6.3.20 Takeda Pharmaceutical Co.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment